Pulmonary Function Testing Systems Market, in terms of revenue, was worth of USD 938.96 million in 2021 and is expected to reach USD 1,406.11 million in 2028, growing at a CAGR of 6.40% from 2022 to 2028.
Lung function tests successfully calculate lung volume, capacity, rates of flow, and gas exchange. This information can help healthcare supplier diagnose and decide the treatment of certain lung disorders. PFTs are generally operated by a respiratory therapist, respiratory physiologist, physiotherapist, pulmonologist, and general practitioner.
Covid-19 has affected the healthcare and has triggered a speedy expansion in health technology with several obvious. Covid 19 directly impacts the lungs and damages the alveoli (tiny air sacs). The respiratory system of a person is of best value for the normal functioning of living and the slightest of dysfunction in it can cause serious breathing issues. Hence, doctors and medical practitioners have been emphasizing on the demand for regular pulmonary checkups of people of all age groups. This has given a push to the growing of the global market for pulmonary function testing systems and has created productive opportunities for market vendors.
Furthermore, extreme consumption of tobacco in the form of cigarette smoking has increased the toll of people suffering from lung cancer. This is one of the leading drivers accelerating the growth of the market worldwide. For example, according to the WHO 2021, over 80% of the world's 1.3 billion tobacco users living in low- and middle-income countries. As well, according to the World Health Organization (WHO), The tobacco epidemic is one of the biggest public health threats the world has ever faced, killing more than 8 million people a year around the world. More than 7 million of those killings are the contact of direct tobacco use while nearly 1.2 million are the result of non-smokers being exposed to second-hand smoke. This is eventually enhancing the demand for pulmonary function testing system across the globe.
|2018 - 2021
|2022 - 2028
|Market Size in 2021:
|USD 938.96 Million
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 1,406.11 Million
|Tables, Charts & Figures:
|Pulmonary Function Testing Systems Comapnies
|AESRI (Vitalograph), COSMED, GE Healthcare, Masimo Corporation, Medical International Research (MIR), MGC Diagnostics Corporation, Midmark Corporation, Nihon Kohden Corporation, NSpire Health, Inc., Philips Healthcare, SCHILLER, Spirometrics, Vyaire Medical, Inc., Others.
|By Type, By Test Type, By Component
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
The future of the pulmonary function testing market appears promising in the upcoming years for an extended period. Different companies are anticipated to implement go-to-market strategies, mergers & acquisitions, and new product launches to remain competitive and meet the escalating demand for pulmonary function testing. Minato, Schiller, MGC Diagnostics, COSMED, Morgan Scientific, Ganshorn, nSpire Health, Sikeda, M&B, AESRI, NDD, CareFusion (BD), and RSDQ, and many more are hugely contributing to in the global market for pulmonary function testing systems market. For example, recently, November 2021, Cipla had launched Spirofy its wireless, portable device capable of performing lung function tests outdoors and in remote areas in India, with the hope of better diagnosing people with pulmonary disease and asthma. Not only this, but also other firms are hugely investing in the pulmonary function testing systems. Such many advancements are contributing to the growth of market.
North America is accounting almost 36% in the pulmonary function testing systems market due to many reasons. Huge presence of major players and technological advancements are making the North America dominating region. Europe is accounting nearly 24.8% market share. Increasing aging population in the region is one of the foremost factors soaring the revenue of the market. According to the Eurostat, in 2019, 18.4% of the EU population aged 15 years or more described that they were daily cigarette smokers. Asia Pacific is fastest growing region with CAGR 7.41%
Analyst Comment, “With more sophisticated technology and enormous investments in the pulmonary function testing systems will result in auspicious growth the market”.
There are several new tools that have been in the market for decades evaluating various aspects of lung function. None of these are widely used, but each has some attractive features that make testing possible in the mainstream. These are grouped below into techniques that evaluate respiratory system mechanics, pulmonary gas exchange, non-invasive cardiac output, and exhaled biomarkers.
The use of forced pressure oscillations applied to open-air is probably the most widely studied. Sophisticated analysis of pressure and flow signals such as oscillations are delivered and reflected back to the device can provide unique insights into airway resistance and reaction. Indeed, this technique is probably complementary to that large airway spirometry, and small airway functions can be distinguished after rest, exercise, and airway challenge. It can also help evaluate the interaction of PEEP and internal PEEP applied in airway obstruction subjects. Since this technique has the ability to measure mechanics during simple tidal respiration, it benefits patients who cannot co-operate with spirometry (e.g., children). However, another innovative approach to evaluating respiratory system mechanics is the use of esophageal balloons to estimate lung pressure. This technique involves inserting an air-filled balloon into the center of the esophagus and then measuring the pressure between the various breathing techniques. Lung disease in significant physical phenotype. Currently, the technique requires complex equipment, skilled operators, and an infusion of solutions. If (and if it is large) clinical utility is shown, simple systems are likely to be followed.
The gold standard for evaluating pulmonary gas exchange is the direct analysis of arterial blood. Pulse oximetry has become more common as an estimate of hemoglobin-oxygen saturation, and extended pulse oximetry capabilities now include carboxyhemoglobin and total hemoglobin. Pulse oximetry, however, cannot measure the partial pressure of oxygen or carbon dioxide, and this non-invasive need is being addressed by the development of transcutaneous technology. Although the accuracy/reproducibility of this technology is greatly affected by capillary perfusion and distance from sensors, reasonable estimates of PCO2 (and to some extent PO2) can be obtained. These instruments have been found to be particularly useful for assessing areas of ischemia surrounding wounds or surgical sites. They are also useful in neonatal/pediatric intensive care units (ICUs), where skin barriers are thin. Their role in adult ICU or pulmonary function (especially exercise) laboratories is less clear but may become significant as technology improves.
Furthermore, the ability of the lungs to absorb carbon monoxide from alveolar gas for carbon monoxide (DLNO) while holding their breath is traditionally used to measure alveolar-capillary air transport. 15 New equipment with fast, real-time gas analysis properties now allows DLNO measurements. A brief trick during exercise, a measurement indicating capillary ""recruitment"" and therefore pulmonary capillary dysfunction may be an early marker. Consumption of nitric oxide from alveolar gas during breath-hold (DLNO) may supplement DLNO. The eclipse of these two gases is conceptually divided into membrane transfer properties and hemoglobin binding properties of the gas. With NO, however, hemoglobin binding is many times faster than hemoglobin-CO binding and thus DLNO primarily reflects the membrane barrier for air exchange. Further study is needed on the clinical utility of separating the membrane and hemoglobin binding components of gas exchange.
It is important to measure the cardiac output to fully evaluate the cardio-respiratory system, but its accurate determination usually requires equipment that invades the right heart / pulmonary artery. The technology for measuring cardiac output (and sometimes lung water) non-invasively has been developed for critical care settings as well as diagnostic (especially exercise) laboratories. While offering reasonably accurate assessments, each of these techniques has significant limitations and usually requires expensive equipment and/or a high level of technical expertise. Nevertheless, the real clinical application may apply in this area of product development as the equipment becomes less costly, reliable, and easy to use.
The ultimate goal of the heart and respiratory system is to deliver oxygen to the tissues. This is currently done by measuring the amount of oxygen flowing through the arterial system and the amount of oxygen returning through the venous system. The use of near-infrared spectroscopy to assess tissue cytochrome reduction/oxygenation status is a new approach. This approach conceptually measures the ""bottom line"" - the direct entry of oxygen into the cytochrome system to produce ATP in vital organs such as the brain. An additional attractive feature is that the device is completely non-invasive. Reliable, reproducible signal processing with minimal artifact intervention is still a challenge and the cost can be significant.
Traditionally, imaging has been the domain of radiology departments. However, it may be reasonable to use radiation-free clever technology in pulmonary function laboratories, as echocardiography has become the mainstay in the diagnostic laboratories of the cardiology department. One such approach is acoustic imaging using an array of microphones on the chest to detect regional lung sounds. The underlying aggregation, airway obstruction, atelectasis, and other things can then be mapped to an image-like format. Another non-invasive imaging technique that will appear in the future pulmonary function laboratory is the use of electrical impedance tomography. It uses electrocardiogram electrodes taped around the chest. Images of gas-filled and ventilated regions can be created using computer analysis of electrical impedance between these various electrodes. This has been studied more extensively in ICU settings, but its location in the Pulmonary Function Lab may allow the assessment of regional lung function in patients without ICU.
By Regional & Country Analysis:
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®